XPHOZAH - tenapanor for phosphate control in adults on dialysis

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use

Dialysis indication and interaction rules matter separately from clearance

XPHOZAH is a phosphate-control product for selected adults with CKD on dialysis, not a universal renal-adjustment instruction for tenapanor. Its source also contains specific separation and enalapril interaction instructions.

Before applying: Confirm the phosphate-binder context, dialysis timing and interacting medicines. The enalapril statement must not be generalized to other ACE inhibitors or used as an automatic dose increase.

Also check: Dialysis indication and interaction rules matter separately from clearance

Official source

XPHOZAH - tenapanor for phosphate control in adults on dialysis

Product / population: XPHOZAH oral tenapanor; phosphate-control indication. Not IBSRELA for IBS with constipation.
Renal measure: Adults with CKD already on dialysis; phosphorus response, tolerability and dialysis timing.

Renal dosing, restrictions and evidence limits

For adult CKD patients on dialysis with inadequate response to phosphate binders or intolerance of any binder dose, the labeled regimen is 30 mg orally twice daily before morning and evening meals. Monitor phosphorus and adjust for gastrointestinal tolerability. Do not take immediately before hemodialysis; take before the next meal after dialysis because diarrhea can follow administration. Stop treatment for severe diarrhea. Separate sodium polystyrene sulfonate by at least 3 hours. Review OATP2B1 interactions, particularly enalapril: the label contains an exception to the usual lower starting-dose advice when coadministered. The dialysis-specific indication is not a general CKD or IBSRELA dosing recommendation.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c57e279c-0f1b-4238-81b7-4e0dc0cc60c5

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

XPHOZAH - tenapanor for phosphate control in adults on dialysis

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

XPHOZAH oral tenapanor; phosphate-control indication. Not IBSRELA for IBS with constipation.

Renal method: Adults with CKD already on dialysis; phosphorus response, tolerability and dialysis timing.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Read 1 difference / caution notes Clinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

indication and interactions

Dialysis indication and interaction rules matter separately from clearance

How to use this: Confirm the phosphate-binder context, dialysis timing and interacting medicines. The enalapril statement must not be generalized to other ACE inhibitors or used as an automatic dose increase.

XPHOZAH - tenapanor for phosphate control in adults on dialysis

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

Official source

XPHOZAH - tenapanor for phosphate control in adults on dialysis

XPHOZAH oral tenapanor; phosphate-control indication. Not IBSRELA for IBS with constipation.

Method: Adults with CKD already on dialysis; phosphorus response, tolerability and dialysis timing.

Renal dosing, restrictions and evidence limits Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope XPHOZAH - tenapanor for phosphate control in adults on dialysis

Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c57e279c-0f1b-4238-81b7-4e0dc0cc60c5

Exact product and population

XPHOZAH oral tenapanor; phosphate-control indication. Not IBSRELA for IBS with constipation.

RDM35-SCOPE-tenapanor-xphozah · Source section: Selected source product scopeRenal section finder

Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official Compare this source

XPHOZAH - tenapanor for phosphate control in adults on dialysis

Open original reference

Open / share this exact local source

DailyMed · XPHOZAH oral tenapanor; phosphate-control indication. Not IBSRELA for IBS with constipation.

Renal method: Adults with CKD already on dialysis; phosphorus response, tolerability and dialysis timing.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

RDM35-official-tenapanor-xphozah-35be174b14-C1 · Source locator: Sections 1, 2, 5.1, 7.1 and 7.2.

Source identity and provenance

Source family: product_label
Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c57e279c-0f1b-4238-81b7-4e0dc0cc60c5
Retrieved: 2026-09-07
Exact label title: XPHOZAH - tenapanor for phosphate control in adults on dialysis
DailyMed Set ID: c57e279c-0f1b-4238-81b7-4e0dc0cc60c5
Renal-function method: Adults with CKD already on dialysis; phosphorus response, tolerability and dialysis timing.
Source date/version: Source revision date not established in selected retrieval.
Hash meaning: SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256: df2e94e98c6257b67f54cd78a1a833f1d6f90eeeb049be0d9c54f6ba82037a3c

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c57e279c-0f1b-4238-81b7-4e0dc0cc60c5
Source retrieval: 2026-09-07. This is not the source publication or label revision date.
Original source type: source summary
Local text SHA-256: f59faf47853b4338b58e06d9d4e8b9443a03877a3dd149513c744490c482577f
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report